Company Profile

LAURUS LABS LTD.

NSE : LAURUSLABSBSE : 540222ISIN CODE : INE947Q01028Industry : Pharmaceuticals & DrugsHouse : Private
BSE365.753.7 (+1.02 % )
PREV CLOSE (Rs.) 362.05
OPEN PRICE (Rs.) 363.20
BID PRICE (QTY) 365.50 (8 )
OFFER PRICE (QTY) 365.95 (168 )
VOLUME 109683
TODAY'S LOW / HIGH (Rs.)363.20 370.10
52 WK LOW / HIGH (Rs.)61.9 385.8
NSE365.90 3.85 (+1.06 % )
PREV CLOSE(Rs.) 362.05
OPEN PRICE (Rs.) 364.85
BID PRICE (QTY) 365.60 (127 )
OFFER PRICE (QTY) 365.95 (143 )
VOLUME 1484294
TODAY'S LOW / HIGH(Rs.) 364.20 370.60
52 WK LOW / HIGH (Rs.)59 385.85

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.03
TTM EPS (Rs.) 14.46
P/E Ratio 25.40
Book Value (Rs.) 41.32
Face Value (Rs.) 2
MCap (Rs. in Mn) 197094.06
Price/Earning (TTM) 20.38
Price/Sales (TTM) 4.69
Price/Book (MRQ) 8.89
PAT Margin (%) 9.55
ROCE (%) 14.41
Incorporation Year : 2005

Management Info :

Malempati Venugopala Rao - Chairman - Managing Director

Registered Office :

Address : Plot No.21, J N Pharma City,Parawada, ,
Vishakhapatnam,
Andhra Pradesh-531021

Phone : 0891 3061222

Website : www.lauruslabs.com

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE
NEWS More
11Feb02-11-2021$Laurus Labs wins coveted Golden Peacock Award for excellence in corporate governance Laurus Labs wins coveted Gol

Laurus Labs has won the prestigious Golden Peacock Award for excellence in corporate governance 2020. Instituted in 1991 by the Institute of Directors (IOD), India, the Golden Peacock Award is regarded as a global stamp of Corporate Excellence. This is the first year that the company has won this coveted award.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs has won the prestigious Golden Peacock Award for ex..
11Feb02-11-2021$Laurus Labs gains on the BSE Laurus Labs gains on the BSE

Laurus Labs is currently trading at Rs. 364.70, up by 5.65 points or 1.57% from its previous closing of Rs. 359.05 on the BSE.

The scrip opened at Rs. 358.00 and has touched a high and low of Rs. 365.65 and Rs. 356.30 respectively. So far 37811 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 385.80 on 25-Jan-2021 and a 52 week low of Rs. 61.90 on 24-Mar-2020.

Last one week high and low of the scrip stood at Rs. 365.00 and Rs. 341.00 respectively. The current market cap of the company is Rs. 19191.58 crore.

The promoters holding in the company stood at 28.76%, while Institutions and Non-Institutions held 24.00% and 47.24% respectively.

Laurus Labs has won the prestigious Golden Peacock Award for excellence in corporate governance 2020. Instituted in 1991 by the Institute of Directors (IOD), India, the Golden Peacock Award is regarded as a global stamp of Corporate Excellence. This is the first year that the company has won this coveted award.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs is currently trading at Rs. 364.70, up by 5.65 poin..
21Jan01-21-2021$Laurus Labs acquires 72.55% stake in Richcore Lifesciences Laurus Labs acquires 72.55%

Laurus Labs has completed acquisition of 72.55% stake in Richcore Lifesciences. With this transaction Richcore Lifesciences has become a subsidiary company of Laurus Labs.

Earlier, the company had signed definitive agreements to acquire a majority stake in Richcore Lifesciences (Richcore). Richcore, a fast-growing biotech company based in Bengaluru with its advanced R&D and manufacturing facilities, develops and manufactures biotech products critical for manufacturing biological drugs.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs has completed acquisition of 72.55% stake in Richco..
21Jan01-21-2021$Laurus Labs gains on acquiring 72.55% stake in Richcore Lifesciences Laurus Labs gains on acquiri

Laurus Labs is currently trading at Rs. 375.75, up by 3.80 points or 1.02% from its previous closing of Rs. 371.95 on the BSE.

The scrip opened at Rs. 375.75 and has touched a high and low of Rs. 379.35 and Rs. 374.75 respectively. So far 0.17 lakh shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 377.30 on 14-Jan-2021 and a 52 week low of Rs. 61.90 on 24-Mar-2020.

Last one week high and low of the scrip stood at Rs. 379.35 and Rs. 352.50 respectively. The current market cap of the company is Rs. 19958.93 crore.

The promoters holding in the company stood at 28.73%, while Institutions and Non-Institutions held 24.00% and 47.27% respectively.

Laurus Labs has completed acquisition of 72.55% stake in Richcore Lifesciences. With this transaction Richcore Lifesciences has become a subsidiary company of Laurus Labs.

Earlier, the company had signed definitive agreements to acquire a majority stake in Richcore Lifesciences (Richcore). Richcore, a fast-growing biotech company based in Bengaluru with its advanced R&D and manufacturing facilities, develops and manufactures biotech products critical for manufacturing biological drugs.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs is currently trading at Rs. 375.75, up by 3.80 poin..
21Jan01-21-2021$Laurus Labs, SpiceJet and Infosys to see some action today Laurus Labs, SpiceJet and In

Laurus Labs has completed acquisition of 72.55% stake in Richcore Lifesciences. With this transaction Richcore Lifesciences has become a subsidiary company of Laurus Labs.  Earlier, the company had signed definitive agreements to acquire a majority stake in Richcore Lifesciences (Richcore). Richcore, a fast-growing biotech company based in Bengaluru with its advanced R&D and manufacturing facilities, develops and manufactures biotech products critical for manufacturing biological drugs.

SpiceJet has added two wide-body planes, a B767 and a A330 model, to its cargo fleet to transport items on long haul routes to destinations such as Europe and the US. With the latest induction, SpiceJet will have a dedicated fleet of 19 cargo aircraft, including five wide-body jets.

Infosys has launched ‘Infosys Cortex’, its customer engagement platform. The platform leverages technology from Genesys, a global leader in cloud customer experience and contact center solutions, along with Contact Center AI services from Google Cloud and its managed artificial intelligence (AI) and analytics services.

Tanla Platforms and Microsoft have launched Wisely, a blockchain-enabled communications platform-as-a-service (CPaaS) offering built on Microsoft Azure. A unique marketplace for enterprises and suppliers, Wisely offers a global edge-to-edge network that delivers private, secure, and trusted communication experiences. Microsoft is the development partner who architected and built this platform for Tanla.

Axis Bank has received approval from Competition Commission of India (CCI) for acquisition of stake in Max Life Insurance. The shareholding of Axis Bank in Max Life will increase to approximately 9.9 per cent. Currently, the bank holds about 1 per cent stake in Max Life and is also the biggest distributor of the insurer's products through banking channel. Additionally, Axis Capital and Axis Securities will acquire 2 per cent and 1 per cent, respectively, shareholding in Max Life.

Sheetal Cool Products has received approval certificate from Export Inspection Council (Ministry of Commerce & Industry) Government of India. The approval certificate is for processing of Ghee, Ice Cream, Kulfi, Indian Sweets, Paneer, Butter, Srikhand and Flavoured Milk for export to Non-EU Countries.

Competition Commission of India (CII) has approved the acquisition of 7.8 per cent minority stake in Aditya Birla Fashion and Retail by Flipkart Investments (FIPL). Aditya Birla Fashion had in October last year approved plans to raise Rs 1,500 crore by issuing a 7.8 per cent stake on a preferential basis to Walmart-owned Flipkart Group.

Laurus Labs has completed acquisition of 72.55% stake in Richco..
Financials More
Rs. in Millions
QTR Dec 20 ANNUAL 20
Net Profit2669.62670.47
Gross Profit 3569.2 3044.82
Operating Profit 4233.15760.46
Net Sales 12722.727973.35
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 14697.05 (1.20%)
M.Cap ( in Cr)
30989.13
Piramal Enterprises (BSE)
 1986.00 (3.55%)
M.Cap ( in Cr)
44234.82
Gland Pharma (BSE)
 2413.00 (2.68%)
M.Cap ( in Cr)
39365.24
Orchid Pharma (BSE)
 1024.60 (5.00%)
M.Cap ( in Cr)
4182.05
Astrazeneca Pharma I (BSE)
 3512.05 (1.19%)
M.Cap ( in Cr)
8790.50
Shareholding Pattern More
NON-INSTITUTION 47.24 %
PROMOTERS 28.76 %
MUTUAL FUNDS/UTI 2.41 %
FI/BANKS/INSURANCE 0 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes